ALEC Logo

Alector, Inc. (ALEC) 

NASDAQ$1.38-0.07 (-4.83%)
Market Cap
$143.67M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
436 of 924
Rank in Industry
257 of 527

ALEC Insider Trading Activity

ALEC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$1,266,60919100

Related Transactions

Yaffe Kristinedirector0$01$25,309$-25,309
Hammond Pauladirector0$01$53,179$-53,179
GRASSO MARCChief Financial Officer0$04$136,917$-136,917
Romano GaryChief Medical Officer0$04$141,413$-141,413
SCHELLER RICHARD Hdirector0$01$228,388$-228,388
Kenkare-Mitra SaraPresident and Head of R&D0$04$240,780$-240,780
Rosenthal ArnonChief Executive Officer0$04$440,623$-440,623

About Alector, Inc.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that â€¦

Insider Activity of Alector, Inc.

Over the last 12 months, insiders at Alector, Inc. have bought $0 and sold $1.27M worth of Alector, Inc. stock.

On average, over the past 5 years, insiders at Alector, Inc. have bought $0 and sold $19.72M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 40,000 shares for transaction amount of $1M was made by Wehner David M. (director) on 2020‑02‑03.

List of Insider Buy and Sell Transactions, Alector, Inc.

2025-03-03SaleRosenthal ArnonChief Executive Officer
40,330
0.0419%
$1.47$59,176+2.11%
2025-03-03SaleKenkare-Mitra SaraPresident and Head of R&D
29,073
0.0302%
$1.47$42,662+2.11%
2025-03-03SaleRomano GaryChief Medical Officer
16,306
0.0169%
$1.47$23,927+2.11%
2025-03-03SaleGRASSO MARCChief Financial Officer
18,091
0.0188%
$1.47$26,547+2.11%
2024-12-02SaleRosenthal ArnonChief Executive Officer
52,172
0.0534%
$2.52$131,442-29.08%
2024-12-02SaleKenkare-Mitra SaraPresident and Head of R&D
26,500
0.0271%
$2.52$66,764-29.08%
2024-12-02SaleRomano GaryChief Medical Officer
14,892
0.0152%
$2.52$37,519-29.08%
2024-12-02SaleGRASSO MARCChief Financial Officer
16,489
0.0169%
$2.52$41,542-29.08%
2024-09-03SaleRosenthal ArnonChief Executive Officer
26,499
0.0282%
$4.88$129,387-53.28%
2024-09-03SaleKenkare-Mitra SaraPresident and Head of R&D
13,926
0.0148%
$4.88$67,981-53.28%
2024-09-03SaleRomano GaryChief Medical Officer
8,478
0.009%
$4.88$41,385-53.28%
2024-09-03SaleGRASSO MARCChief Financial Officer
7,297
0.0078%
$4.88$35,620-53.28%
2024-08-22SaleSCHELLER RICHARD Hdirector
44,250
0.0463%
$5.16$228,388-50.30%
2024-08-12SaleYaffe Kristinedirector
5,000
0.0051%
$5.06$25,309-28.77%
2024-08-12SaleHammond Pauladirector
10,500
0.0108%
$5.06$53,179-28.77%
2024-06-03SaleRosenthal ArnonChief Executive Officer
25,135
0.0249%
$4.80$120,618-9.74%
2024-06-03SaleKenkare-Mitra SaraPresident and Head of R&D
13,206
0.0131%
$4.80$63,373-9.74%
2024-06-03SaleRomano GaryChief Medical Officer
8,040
0.008%
$4.80$38,582-9.74%
2024-06-03SaleGRASSO MARCChief Financial Officer
6,920
0.0068%
$4.80$33,208-9.74%
2024-03-04SaleRosenthal ArnonChief Executive Officer
18,837
0.0195%
$6.92$130,386-29.30%
Total: 150
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
GORDON CARL L
10434976
10.5312%
$15.13M10+10.01%
ORBIMED ADVISORS LLC10 percent owner
1906718
1.9243%
$2.76M117+10.01%
Wehner David M.director
44621
0.045%
$64,700.4510<0.0001%

Historical Insider Profitability vs. Competitors

$30,470,407
140
20.39%
$134.78M
$860,541,348
82
-5.10%
$132.49M
$2,924,567
72
-4.87%
$157.74M
$909,129
37
42.19%
$127.55M
$35,190,048
32
37.32%
$150.49M

ALEC Institutional Investors: Active Positions

Increased Positions79+42.93%20M+27.35%
Decreased Positions75-40.76%19M-26.21%
New Positions31New17MNew
Sold Out Positions39Sold Out11MSold Out
Total Postitions188+2.17%73M+1.14%

ALEC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$21,300.0014.84%14.69M+94,851+0.65%2024-12-31
Ra Capital Management, L.P.$14,058.009.79%9.7M+10MNew2024-12-31
Blackrock, Inc.$13,248.009.23%9.14M-215,297-2.3%2024-12-31
Vanguard Group Inc$8,144.005.67%5.62M+160,652+2.94%2024-12-31
Merck & Co., Inc.$5,141.003.58%3.55M+4MNew2024-12-31
Geode Capital Management, Llc$2,776.001.93%1.91M+10,308+0.54%2024-12-31
State Street Corp$2,681.001.87%1.85M-767,514-29.33%2024-12-31
Jpmorgan Chase & Co$2,382.001.66%1.64M-1M-39.81%2024-12-31
Euclidean Capital Llc$1,896.001.32%1.31M00%2024-12-31
Deutsche Bank Ag$1,604.001.12%1.11M-48,050-4.16%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.